Black cancer patients better represented in publicly-funded clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Black patients are better represented in taxpayer-funded clinical trials testing new cancer treatments compared to trials run by pharmaceutical companies, according to a study conducted by SWOG Cancer Research Network, a member of NCI’s National Clinical Trials Network.

The study also found that black patients are not fully represented in cancer clinical trials.

The results are published in JNCI Cancer Spectrum, and were presented as a poster in the 2020 American Association for Cancer Research virtual annual meeting II.

A companion network to NCTN, the NCI Community Oncology Research Program runs prevention and cancer care delivery trials, and includes community and rural hospitals in its network, including sites with significant minority and underserved patient populations.

About 25% of all NCORP trial volunteers are racial and ethnic minorities. Both NCTN and NCORP trials are designed by doctors, paid for with public funds from the NIH through the NCI, and powered by patient volunteers.

The study compared black enrollment in NCI-sponsored trials and industry-sponsored trials.

“Everyone can get cancer, so everyone should have the same access to investigational cancer treatments,” Joseph Unger, a SWOG biostatistician and health services researcher based at Fred Hutchinson Cancer Research Center, who specializes in cancer disparities research with a focus on the impacts of insurance status, race and ethnicity, and income on health outcomes, said in a statement. “In addition, it’s very important from a scientific standpoint to evaluate new treatments in patients who reflect the demographics of the general cancer population.”

To conduct the study, Unger and his team used three databases. One was the SWOG trials database, used as a proxy to estimate the rate of participation among NCI trials. Unger’s colleagues, led by Kanwal P.S. Raghav, of MD Anderson Cancer Center and Jonathan M. Loree, of BC Cancer, created a database of pharmaceutical company-sponsored trials that supported new drug applications and included data on trial participation by race.

The team also used data from the NCI’s Surveillance, Epidemiology and End Results program, as well as data compiled by the U.S. Census Bureau, to estimate the expected rate of black participation in the cancers they studied.

Unger and his team analyzed data from a total of 358 trials—85 industry trials and 273 SWOG trials—that enrolled 93,825 patients being treated for 15 different cancer types. Enrollments spanned the years 2003-2018. In those 15 cancers, the rate of black enrollment in industry trials was 3% compared to 9% in SWOG trials, and 12% in the corresponding U.S. cancer population/.

“This study confirmed that black cancer patients are severely underrepresented in pharmaceutical company sponsored trials, with fewer than one in four of the expected number enrolled,” Unger said. “Black representation in industry trials was also far below that of NCTN trials, with only one black patient enrolled for every three enrolled in NCTN trials.”

FDA and AACR are examining how to improve representation of black patients in FDA registration trials. Registration trials are specially designed studies conducted with the expectation that the data they produce will be used to apply to the FDA for new drug approval, or to expand the uses of a currently approved cancer drug. Unger serves on this FDA and AACR task force.

“NCI sponsored trials have a broader mandate,” Unger said. “They reach beyond just the major cancer centers to serve patients in a more diverse community-based clinical setting. This could serve as a model for pharma trials aiming to increase representativeness of all patients.”

Unger’s study was funded by the NIH through NCI grant award CA189974 and CA189873 and in part by The Hope Foundation for Cancer Research and the Michael Smith Health Professional Investigator program.

Unger’s research team included Dawn Hershman, of Columbia University; Raymond U. Osarogiagbon, of Baptist Cancer Center; Anirudh Gothwal, of Baylor University; Seerat Anand, of MD Anderson Cancer Center; Arvind Dasari, of MD Anderson Cancer Center; Michael Overman, of MD Anderson Cancer Center; Jonathan M. Loree, of BC Cancer; and Kanwal Raghav, of MD Anderson Cancer Center.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login